Therapeutic chemokine receptor antagonists

Details Therapeutic chemokine receptor antagonists Therapeutic chemokine receptor antagonists

2005-09-20

2005-09-20

Kemmerer, Elizabeth (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S085400, C514S002600, C514S016700, C530S300000, C530S323000, C530S328000

Reexamination Certificate

active

06946445

ABSTRACT:
The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments. CXCR4 antagonsits may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.

REFERENCES:
patent: 2530369 (1950-11-01), Simons et al.
patent: 2760992 (1956-08-01), Schoeffel et al.
patent: 4554101 (1985-11-01), Hopp et al.
patent: 5807744 (1998-09-01), Berneman et al.
patent: 5856301 (1999-01-01), Craig et al.
patent: 5919776 (1999-07-01), Hagmann et al.
patent: 5962462 (1999-10-01), Mills et al.
patent: 5990163 (1999-11-01), Evans et al.
patent: 6013644 (2000-01-01), Mills et al.
patent: 6022848 (2000-02-01), Kozlov et al.
patent: 6046185 (2000-04-01), Burgoyne et al.
patent: 6124319 (2000-09-01), MacCoss et al.
patent: 6132987 (2000-10-01), Charo et al.
patent: 6133319 (2000-10-01), Widdowson et al.
patent: 6136827 (2000-10-01), Caldwell et al.
patent: 6140349 (2000-10-01), Caldwell et al.
patent: 6166037 (2000-12-01), Budhu et al.
patent: 6204294 (2001-03-01), Bryan et al.
patent: 6613742 (2003-09-01), Huang et al.
patent: 2002/0156034 (2002-10-01), Tudan et al.
patent: 2003/0202963 (2003-10-01), Crystal et al.
patent: WO 98/04698 (1998-02-01), None
patent: WO 00/09152 (2000-02-01), None
Wells (Sep. 18, 1990) “Additivity of Mutational Effects in Proteins.” Biochemistry 29(37): 8509-8517.
Ngo et al. (Mar. 2, 1995) “The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox” pp. 433-506.
Bork (2000) “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle.” Genome Research 10:398-400.
Skolnick and Fetrow (2000) “From gene to protein structure and function: novel applications of computational approaches in th genomic ara.” Trends in Biotech. 18(1): 34-39.
Doerks et al. (Jun. 1998) “Protein annotation: detective work for function prediction.” Trends in Genetics 14(6): 248-250.
Smith and Zhang (Nov. 1997) “The challenges of genome sequence annotation or ‘The devil is in the details’.” Nature Biotechnology 15: 1222-1223.
Brenner (Apr. 1999) “Errors in genome annotation.” Trends in Genetics 15(4): 132-133.
Bork and Bairoch (Oct. 1996) “Go hunting in sequence databases but watch out for the traps.” Trends in Genetics 12(10): 425-427.
Heveker et al. (Mar. 26, 1998) “Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides.” Curr Biol. 8(7): 369-376.
Acsadi, G. et al, “Human Dystrophin Expression in MDX Mice After Intramuscular Injection of DNA Constructs” (1991)Naturevol. 352, 815-818.
Alkhatib, G. et al, “CC CKR5: A RANTES, MIP-1α, MIP-β, Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1” (1996)Sciencevol. 272, 1955-1958.
Allen, M. et al, “High Throughput Fluorescence Polarization: A Homogeneous Alternative to Radioligand Binding for Cell Surface Receptors” (2000)J. Biomolecular Screeningvol. 5 No. 2, 63-69.
Anderlini, P. et al., “Allogenic Blood Stem Cell Transplantation: Considerations for Donors” (1997)Bloodvol. 90 No. 3, 903-908.
Anderson, W. et al, “The Best of Times, the Worst of Times” (2000)Sciencevol. 288, 627-629.
Arenzana-Selsdedos, F. et al, “HIV Blocked by Chemokine Antagonist” (1996)Naturevol. 383, 400.
Avenarius, H. et al, “Granulocyte Colony-stimulating Factor Enhances the Expression of CD62 on Platelets in vivo” (1993)Inter. J. Hematologyvol. 58, 189-196.
Baggiolini, M. “Chemokines and Leukocyte Traffic” (1998)Naturevol. 392, 565-568.
Barbier, J. et al, “Bioactivities and Secondary Structures of Constrained Analogues of Human Parathyroid Hormone: Cyclic Lactams of the Receptor Binding Region” (1997)J. Med. Chem. vol. 40 No. 9, 373-1380.
Barbier, J. et al, “Structure and Activities of Constrained Analogues of Human Parathyroid Hormone and Parathyroid Hormone-Related Peptide: Implications for Receptor-Activting Conformtations of the Hormones” (2000)Biochemistry 2000vol. 39 No. 47, 14522-14530.
Barnes, D. et al, “Polyclonal Antibody Directed Against Human RANTES Ameliorates Disease in the Lewis Rat Adjuvant-Induced Arthritis Model” (1998)J. Clin. Invest. vol. 101 No. 12., 2910-2919.
Blease, K. et al, “Airway Remodeling is Absent in CCR1-—/—Mice During Chronic Fungal Allergic Airway Disease” (2000)J. Immunol. vol. 165, 1564-1572.
Brandt, J. et al, “Cytokine-dependent Long-Term Culture of Highly Enriched Precursors of Hematopoietic Progenitor Cells from Human Bone Marrow” (1990)J. Clin. Invest., vol. 86, 932-941.
Brandt, J. et al, “Role of c-kit Ligand in the Expansion of Human Hematopoietic Progenitor Cells” (1992)Bloodvol. 79 No. 3, 634-641.
Brandt, J. et al, “Characterization of a Human Hematopoietic Progenitor Cell Capable of Forming Blast Cell Containing Colonies in vitro” (1998)J. Clin. Invest. vol. 82, 1017-1027.
Buckley, C. et al, “Persistent Induction of the Chemokine Receptor CXCR4 by TGF-β1 on Synovial T Cells Contributes to Their Acumulation within the Rheumatoid Synovium” (2000)J. Immunol. vol. 165, 3423-3429.
Burt, R., “Hematopoietic Stem Cell Transplantation: A New Therapy for Autoimmune Disease” (1999)Stem Cellsvol. 17, No. 6, 366-372.
Campbell, J. et al, “Chemokines and the Arrest of Lymphocytes Rolling Under Flow Conditions” (1998).Sciencevol. 279, 381-383.
Cashman, J. et al, “Differentiation Stage-Specific Regulation of Primitive Human Hematopoietic Progenitor Cycling by Exogeneous and Endogeneous Inhibitors in an in Vivo Model” (1999)Bloodvol. 94 No. 11, 3722-3729.
Cavazzana-Calvo, M. et al, “Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease” (2000)Sciencevol. 288, 669-672.
Charo, O. et al, “Molecular Cloning and Functional Expression of Two Monocyte Chemoattractant Protein 1 Receptors Reveals Alternative Splicing of the Carboxyl-terminal Trails” (1994)Proc. Natl. Acad. Sci.vol. 91, 2752-2756.
Choe, H. et al, “The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolatas” (1996)Cellvol. 85, 1135-1148.
Clapp, W. et al, “Fetal Liver Hematopoietic Stem Cells as a Target for In Utero Retroviral Gene Transfer” (1991)Bloodvol. 78 No. 4, 1132-1139.
Combadiere, C. et al, “Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor” (1995)J. Biol. Chem. vol. 270, 16491-16494.
Conti, J. et al, “Acute Arterial Thrombosis After Escalated-Dose Methotrexate, Vinoblastine, Doxorubicin, and Cisplatin Chemotherapy with Recombinant Granulocyte Colony-Stimulating Factor” (1992)Cancervol. 70 No. 11, 2699-2702.
Cushing, S. et al, “Minimally Modified Low Density Lipoprotein Induces Monocyte Chemotactic Protein 1 in Human Endothelial Cells and Smooth Muscle Cells” (1990)Proc. Natl. Acad. Sci. vol. 87, 5234-5138.
Demirer, T. et al, “Optimization of Peripheral Blood Stem Cell Mobilization” (1996)Stem Cellsvol. 14, 106-116.
Deng, H. et al, “Identification of a Major Co-receptor for Primary Isola

Affiliated with

Also associated with

Rating

Therapeutic chemokine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic chemokine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic chemokine receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3431849